Leo Pharma disappoints as deficit surpasses USD 720m
![Photo: MAGNUS MØLLER](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13794409.ece/ALTERNATES/schema-16_9/doc7jyu218q6zdoka729mk.jpg)
Revenues are down as the bottom line deficit at Leo Pharma grows, the company’s annual report for 2021 reveals.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Small molecules to lead Leo Pharma to greatness
For subscribers
Layoffs and restructuring will prepare Leo Pharma for IPO
For subscribers